Jyong Biotech Long Term Debt 1970-1969 | MENS

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Jyong Biotech long term debt from 1970 to 1969. Long term debt can be defined as the sum of all long term debt fields.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Jyong Biotech long term debt from 1970 to 1969. Long term debt can be defined as the sum of all long term debt fields.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$247.8B
Amgen (AMGN)	$154.9B
Gilead Sciences (GILD)	$140.2B
Vertex Pharmaceuticals (VRTX)	$100.3B
Bristol Myers Squibb (BMY)	$96B
GSK (GSK)	$80.8B
CSL (CSLLY)	$67.1B
Regeneron Pharmaceuticals (REGN)	$61.5B
Alnylam Pharmaceuticals (ALNY)	$58.5B
Argenex SE (ARGX)	$43.6B
Insmed (INSM)	$28.8B
BioNTech SE (BNTX)	$24B
Royalty Pharma (RPRX)	$21B
Biogen (BIIB)	$19.4B
Incyte (INCY)	$16.5B
Genmab (GNMSF)	$16.5B
Genmab (GMAB)	$16B
Illumina (ILMN)	$15.4B
Ascendis Pharma (ASND)	$11.9B
BioMarin Pharmaceutical (BMRN)	$11.2B
Swedish Orphan Biovitrum (BIOVF)	$10.9B
QIAGEN (QGEN)	$10.3B
Exelixis (EXEL)	$10.1B
Moderna (MRNA)	$9.4B
Verona Pharma American Depositary Share (VRNA)	$9.2B
Exact Sciences (EXAS)	$9B
Bio-Techne Corp (TECH)	$8.6B
Halozyme Therapeutics (HALO)	$8.6B
Guardant Health (GH)	$8.4B
Blueprint Medicines (BPMC)	$8.3B